This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Common subtypes of MODY

Authoring team

Maturity onset diabetes of the young (MODY) is a heterogeneous group of monogenic disorders distinct from type 1 (insulin-dependent) and type 2 (noninsulin-dependent) diabetes (1).

  • there is β cell dysfunction characterised by non-ketotic diabetes and absence of pancreatic auto-antibodies (2)

common subtypes of MODY

Clinical presentation, prognosis, and treatment response varies with the subtype of MODY e.g. -

  • GCK
    • often asymptomatic and recognised during routine screening
    • there is mild, stable fasting hyperglycaemia (5.5 - 8 mmol/L)
    • majority maintain glycated hemoglobin (HbA1c level) below 8%,
    • around 2% require insulin therapy
    • complications are rare
    • about 50% of female carriers develop gestational diabetes (2)

  • HNF1A
    • most common cause of MODY in the UK
    • there is progressive beta cell failure and increasing hyperglycemia
    • low renal threshold for glycosuria
    • raised HDL-C levels are seen which will differentiate MODY with type 2 diabetes
    • marked sensitivity to sulfonylureas
    • considerable risk of microvascular and macrovascular complications

  • HNF4A
    • usually are normoglycaemic in childhood but progressive beta cell dysfunction results in diabetes during the second to fifth decades
    • treatment requirement increases with time and may require insulin therapy
    • vulnerable to the microvascular and macrovascular complications associated with diabetes
    • macrosomia and neonatal hypoglycaemia have also been reported
    • tight control sugar and other cardiovascular risk factors are vital in long term care

Prevalence of MODY is unknown but the minimum UK population prevalence of all MODY subtypes is estimated to be 68-108 cases per million.

Notes:

  • the prevalence of MODY subtypes differ from country to country
    • in countries such as France, Spain, and Italy where glucose testing of asymptomatic people is done routinely, glucokinase (GCK) mutations are commonly diagnosed while in countries where random blood glucose tests are seldom done hepatocyte nuclear factor 1α (HNF1A) is commonly daiagnosed.
  • in the UK, most common causes of mutations of MODY are
    • glucokinase (GCK) - 32%
    • hepatocyte nuclear factor 1α (HNF1A) - 52%
    • hepatocyte nuclear factor 4α (HNF4A) - 10% (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.